HPV Country Profile

Statistics and Data Analytics


cases in 2018



deaths in 2018

Status of National HPV Vaccination Programme

The HPV vaccine is currently not included in Turkey’s national immunization program.


General Information

Human Papillomavirus

Burden of HPV infection

In Turkey, about 4.7% of women in the general population are estimated to have HPV type 16 or 18 at a given time, which causes approximately 76.0% of invasive cervical cancers in the country. Approximately 25% of women have any type of HPV, according to a 2013 study.1,4

Burden of cervical cancer

Cervical cancer, caused by HPV, is the fifteenth leading cause of cancer deaths in women in Turkey, causing at least 1280 deaths annually among the population of 31.1 million women aged 15 years and older who are at risk for the disease.1,2 Between 2012 and 2018, the number of deaths every year due to cervical cancer nearly doubled (663 in 2012 to 1280 in 2018), and if decisive action is not taken at the national level, annual deaths due to the disease will nearly double again by 2040, reaching 2210 deaths per year.3 In Turkey, at least 2356 women are newly diagnosed with cervical cancer each year.

4.8 per 100,000 women in Turkey contract cervical cancer annually and 2.5 per 100,000 women die due to the disease each year in Turkey. Compared to countries in the MENA region (as defined by UNAIDS), Turkey’s death and incidence rates due to cervical cancer are relatively low. For example, Somalia and Morocco have the highest incidence and mortality rates, with 24.0 and 17.2 women per 100,000 being newly diagnosed with cervical cancer annually and at least 21.9 and 12.6 women per 100,000 dying due to cervical cancer per year, respectively. Whereas Iran, Iraq and Yemen have the lowest (around 2 per 100,000 women are diagnosed per year and about 1 per 100,000 die because of cervical cancer annually).2

Cervical cancer incidence and mortality rate projections
Research and Publications
  1. Gultekin, Murat, et al. “Mega Hpv Laboratories for Cervical Cancer Control: Challenges and Recommendations from a Case Study of Turkey.” Papillomavirus Research, vol. 7, June 2019, pp. 118–22, doi:10.1016/j.pvr.2019.03.002.
  2. Korkut, Yasemin. “Assessment of Knowledge, Attitudes, and Behaviors Regarding Breast and Cervical Cancer among Women in Western Turkey.” Journal of International Medical Research, Mar. 2019, p. 030006051983025, doi:10.1177/0300060519830252.
  3. Cift, Tayfur, et al. “Assessment of Knowledge and Attitudes of Midwives and Nurses Working at the Hospital about HPV Infection and Vaccinations.” European Journal of Obstetrics and Gynecology and Reproductive Biology, vol. 234, Mar. 2019, p. e176, doi:10.1016/j.ejogrb.2018.08.546.
  4. Aydoğmuş, Hüseyin, and Serpil Aydoğmuş. “Comparison of Colposcopic Biopsy Results of Patients Who Have Cytomorphological Normal but HPV 16-18 or Other High-Risk HPV Subtypes Positive.” Asian Pacific Journal of Cancer Prevention: APJCP, vol. 20, no. 2, Feb. 2019, pp. 417–20, doi:10.31557/APJCP.2019.20.2.417.
  5. Erdoğan, Bahattin, et al. “Analysis of Cervical Liquid-Based Cytology Results in Eskişehir, Turkey: Correlation of Cytology Results with Histology, Immunocytocemical HPV Ab and HPV DNA Results of 18404 Women.” International Journal Of Community Medicine And Public Health, vol. 6, no. 3, Feb. 2019, pp. 943–49, doi:10.18203/2394-6040.ijcmph20190576.
  6. Comba, Cihan, and Omer Demir. Why Are Cervical Smear Abnormalities Frequency Increasing in Turkey? 2019, p. 4.
  7. Seneldir, Hatice, and Gozde Kir. “Prevalence of High-Risk Human Papilloma Virus in Liquid-Based Cervical Samples from Turkish Women with Normal and Abnormal Cytology.” Diagnostic Cytopathology, vol. 47, no. 2, 2019, pp. 100–04, doi:10.1002/dc.24022.
  8. Ozaydin-Yavuz, Goknur, et al. “Determinants of Hgh-Risk Human Papillomavirus Infection in Anogenital Warts.” Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, vol. 36, no. 1, 2019, pp. 76–81, doi:10.5114/ada.2019.82915.
  9. Akay, Ebru, et al. “Concordance of the Frequency, Typing, and Results of High Risk Human Papilloma Virus in Cervical Cytology Materials with Biopsy: Retrospective Analysis of 5604 Patients -.” Annals of Medical Research, vol. 26, no. 2, 2019, pp. 180–84, http://www.scopemed.org/?mno=1006363.
  10. Özdemir, Raziye, et al. “Challenges in Cancer Control Services Provided by Family Physicians in Primary Care: A Qualitative and Quantitative Study From Karabuk Province in Turkey.” Journal of Cancer Prevention, vol. 23, no. 4, Dec. 2018, pp. 176–82, doi:10.15430/JCP.2018.23.4.176.
  11. Göktuğ, B. Kadıoğlu, et al. “Relation of cervical cancer with the results of human papillomavirus (HPV) screening carried out via hybrid capture 2 method on 52.000 women in Erzurum.” Mikrobiyoloji bulteni, vol. 52, no. 4, Oct. 2018, pp. 367–75, doi:10.5578/mb.67419.
  12. Unlu, Ahmet, et al. “National Survey Study on the Approaches of Pediatricians, Family Physicians, Medical Oncologists and Gynecologists to the HPV Vaccine.” Journal of Oncological Sciences, vol. 4, no. 2, Aug. 2018, pp. 74–79, doi:10.1016/j.jons.2018.04.002.
  13. Oz, Murat, et al. “Awareness and Knowledge Levels of Turkish College Students about Human Papilloma Virus Infection and Vaccine Acceptance.” Journal of Cancer Education, vol. 33, no. 2, Apr. 2018, pp. 260–68, doi:10.1007/s13187-016-1116-0.
  14. Barut, Mert Ulaş, et al. “Human Papilloma Viruses and Their Genotype Distribution in Women with High Socioeconomic Status in Central Anatolia, Turkey: A Pilot Study.” Medical Science Monitor : International Medical Journal of Experimental and Clinical Research, vol. 24, Jan. 2018, pp. 58–66, doi:10.12659/MSM.906652.
  15. Gultekin, Murat, et al. “Initial Results of Population Based Cervical Cancer Screening Program Using HPV Testing in One Million Turkish Women.” International Journal of Cancer, vol. 142, no. 9, 01 2018, pp. 1952–58, doi:10.1002/ijc.31212.
View all publications
  1. Bruni L, Barrionuevo-Rosas L, Albero G, Serrano B, Mena M, Gómez D, Muñoz J, Bosch FX, de Sanjosé S. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in Turkey. Summary Report 27 July 2017. [19 October, 2018]

  2. Cancer Today. (2018, September). Retrieved October 19, 2018, from https://gco.iarc.fr/.

  3. Cancer Tomorrow. (2018, September). Retrieved October 19, 2018, from https://gco.iarc.fr/.

  4. Dursun et al. (2013). HPV Types in Turkey: Multicenter Hospital Based Evaluation of 6388 Patients in Turkish Gynecologic Oncology Group Centers / Türkiye’deki HPV Tipleri: Türk Jinekolojik Onkoloji Grubuna Üye Merkezlere Başvuran 6388 Hastanın Retrospektif Analizi, Turkish Journal of Pathology, 29(3), 210-216. doi: https://doi.org/10.5146/tjpath.2013.01188

Please notify us if you know of other resources, including academic publications, news articles and information that should be added to this page by emailing: hpvmena@gmail.com.